Overview
Morella cerifera pollen is the pollen of the Morella cerifera plant. Morella cerifera pollen is mainly used in allergenic testing.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Nelco Laboratories, Inc. | 36987-2510 | INTRADERMAL, SUBCUTANEOUS | 10000 [PNU] in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2513 | INTRADERMAL, SUBCUTANEOUS | 40000 [PNU] in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2516 | INTRADERMAL, SUBCUTANEOUS | 0.1 g in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2514 | INTRADERMAL, SUBCUTANEOUS | 0.05 g in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2515 | INTRADERMAL, SUBCUTANEOUS | 0.05 g in 1 mL | 12/3/2009 | |
| Antigen Laboratories, Inc. | 49288-0079 | INTRADERMAL, SUBCUTANEOUS | 0.05 g in 1 mL | 11/19/2009 | |
| Nelco Laboratories, Inc. | 36987-2511 | INTRADERMAL, SUBCUTANEOUS | 20000 [PNU] in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2512 | INTRADERMAL, SUBCUTANEOUS | 20000 [PNU] in 1 mL | 12/3/2009 | |
| Nelco Laboratories, Inc. | 36987-2509 | INTRADERMAL, SUBCUTANEOUS | 10000 [PNU] in 1 mL | 12/3/2009 | |
| Allergy Laboratories, Inc. | 54575-909 | PERCUTANEOUS, SUBCUTANEOUS | 1 g in 20 mL | 3/15/2011 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Beauty Collagen Antiox-14 | 375116 | Medicine | A | 9/22/2021 | |
| Emulin 5 | 481850 | Dr Joseph Ahrens Pty Ltd trading as ATM International | Medicine | A | 3/6/2025 |
| LOQUAT LEAF COUGH SYRUP -[ZHIKE PIPA LU] | 142848 | Medicine | A | 8/6/2007 | |
| HRF | 63313 | Medicine | A | 2/17/1998 | |
| Sports Recoup | 347699 | Dr Joseph Ahrens Pty Ltd trading as ATM International | Medicine | A | 11/9/2020 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.